Bpifrance

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

MB Therapeutics is a pharmaceutical company that specializes in patient-centric solutions for the development and production of tailored medicines. It operates a system that enables the creation of customized medications, including the combination of multiple active ingredients into a single unit, and offers evaluation services. The company's focus is on enhancing treatment precision and improving patient adherence through the customization of medication dosage and forms.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Fudzs is a pioneer in the sustainable bioeconomy, specializing in the development of eco-friendly cell bioproduction processes utilizing advanced bioreactor technology. The company focuses on the mass production of cells through innovative biomaterial engineering combined with cellular science, which enables cost-effective solutions for various industries. Fudzs aims to revolutionize the cultivated meat sector by creating affordable and high-quality meat alternatives, as well as enhancing cell therapies. Its proprietary approach to biomaterials is optimized for cell growth, significantly increasing cell amplification and density in bioreactors, thereby unlocking new market opportunities and promoting a more sustainable future in food production and healthcare.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Ynsect is a biotechnology company based in Evry, France, that specializes in the production and processing of insects for sustainable animal feed and non-food applications. Founded in 2011, Ynsect operates insect vertical farms that convert insects into high-quality nutrition products, including proteins and lipids for livestock and pet diets. The company employs innovative bioconversion techniques to utilize organic resources, producing not only animal feed but also organic fertilizers, bioenergy, and other valuable materials. Ynsect's expertise in large-scale insect farming and automation has positioned it as a leading provider in the agro-food and environmental biotech sectors, making it a favored partner for agricultural professionals, research institutions, and investors.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Mycophyto, co-founded in July 2016 by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise, specializes in biological crop protection based on three decades of research. The company develops customized products and offers specific support services to facilitate innovative agricultural systems. Mycophyto's plant production system focuses on identifying indigenous fungi and beneficial soil pathogens that enhance plant growth. By cultivating these microorganisms in an integrated greenhouse, the company enables researchers to grow a variety of plants, crops, and herbs sustainably, reducing dependence on chemical fertilizers. Through its unique approach, Mycophyto aims to advance agricultural practices while promoting environmental sustainability.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Carroucell specializes in providing microcarriers for cell culture in bioreactors. The company has developed a unique microscopic matrices platform that features flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing processes by addressing common performance challenges associated with traditional cell culture methods. Carroucell's products are tailored to meet the needs of customers in the biopharmaceutical industry, facilitating improved outcomes in cell culture applications.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

INTERSTELLAR LAB is focused on creating innovative, environment-controlled pods designed for crop cultivation. The company develops and manufactures advanced bio-farming platforms that serve as regenerative habitats, automatically regulating essential environmental factors such as air, pressure, water, temperature, and humidity. This technology aims to provide optimal conditions for both plants and humans, facilitating the sustainable production of plant-based ingredients. By enabling the agricultural sector to cultivate a diverse range of fruits, vegetables, flowers, and other plants in various locations, INTERSTELLAR LAB supports large health, beauty, and food and beverage companies in sourcing clean, high-quality ingredients. Additionally, the company is also working on developing space-inspired villages on Earth, aligning with its vision of sustainability and innovation in agriculture.

Cell-Easy SAS is a contract development and manufacturing organization based in Toulouse, France, specializing in stem cell services for preclinical and clinical drug development. Founded in 2017, the company focuses on providing ready-to-inject adipose-derived allogeneic stem cells, utilizing biological material from healthy donors. This approach enables the healthcare industry to reduce manufacturing costs associated with stem cell therapies, addressing affordability challenges in the field. By streamlining access to these stem cells, Cell-Easy supports various development projects aimed at improving patient outcomes.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Diaccurate is a biotechnology company based in Paris, France, that focuses on researching and developing treatments for various diseases, including HIV infection and several types of cancer. Founded in 2012, the company targets conditions such as endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring innovative therapeutic approaches in oncology, aiming to provide effective solutions for patients facing these challenging and often incurable diseases.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a privately-owned biotech company focused on developing advanced chemotherapies that specifically target the microenvironment of solid tumors. Its innovative approach aims to deliver potent anticancer agents while minimizing harm to healthy tissues, thereby reducing adverse effects for cancer patients. The company's "smart drugs" are designed to selectively transport these agents, utilizing a targeting unit for effective recognition of malignant cells. Additionally, Seekyo's technology incorporates a versatile enzyme-responsive self-immolative linker that enables controlled drug release exclusively at the tumor site. This targeted methodology seeks to enhance the efficacy and safety of cancer treatments, offering patients a more tolerable therapeutic option.

Argobio is a start-up studio focused on developing innovative therapeutic solutions and fostering the growth of biotech firms. It collaborates with leading European academic research institutes to identify and nurture early-stage projects, particularly in the areas of rare diseases, neurological disorders, oncology, and immunology. By providing financial support and operational expertise, Argobio aims to cultivate these projects before launching them as independent companies. The studio also seeks to create promising platform technologies that can lead to new therapeutic products, thereby enhancing the drug research and development process for startups in the biotechnology sector.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Honing Biosciences SAS is a bio-therapeutics company based in Paris, France, specializing in the development and enhancement of cell-based therapies for cancer and other chronic diseases. The company utilizes its proprietary molecular CellTune technology to create tunable cell therapeutics that enable precise control over the dynamic delivery of proteins in patients. This innovation allows for the regulation of protein expression at the cell surface and the secretion of therapeutic agents such as enzymes, cytokines, and antibodies, which can be adapted based on the clinical progression of a patient's condition. Honing Biosciences also offers therapies like CAR-T cell therapy and checkpoint inhibitors, which aim to improve treatment efficacy while minimizing adverse effects associated with earlier therapeutic generations. Established in 2018, the company focuses on advancing immunotherapy and reconstituting cell therapies to better engage the body’s immune system in combating diseases.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company leverages the unique properties of tumor hallmarks and the tumor microenvironment to create targeted antibody-drug conjugates (ADCs) that feature optimal drug-to-antibody ratios. By doing so, Syndivia aims to enhance antitumor efficacy and improve safety for cancer patients, ultimately striving to deliver the most effective treatments available.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Aelis Farma S.A.S. is a biotechnology company based in Bordeaux, France, established in 2013. The company specializes in the research and development of pregnenolone derivatives aimed at treating cannabis addiction. Aelis Farma is recognized for its innovative approach in developing signaling-specific therapeutics that target G protein-coupled receptors (GPCRs), particularly the CB1 receptor, which is widely expressed in the brain. By focusing on these receptors, Aelis Farma aims to create treatments that can selectively modulate signaling pathways, minimizing unwanted side effects commonly associated with conventional GPCR-targeting drugs. The company's work addresses critical needs in the treatment of brain diseases and addiction.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Ynsect is a biotechnology company based in Evry, France, that specializes in the production and processing of insects for sustainable animal feed and non-food applications. Founded in 2011, Ynsect operates insect vertical farms that convert insects into high-quality nutrition products, including proteins and lipids for livestock and pet diets. The company employs innovative bioconversion techniques to utilize organic resources, producing not only animal feed but also organic fertilizers, bioenergy, and other valuable materials. Ynsect's expertise in large-scale insect farming and automation has positioned it as a leading provider in the agro-food and environmental biotech sectors, making it a favored partner for agricultural professionals, research institutions, and investors.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Discngine specializes in providing scientific computing consulting services and solutions tailored for life sciences research. The company develops software applications designed for life-science researchers, offering a SaaS-based data acquisition platform that enhances the discovery of innovative molecules. This platform supports high-content screening experiments, organizes and stores experimental results from diverse sources, and facilitates primary and secondary screening of outcomes, including dose-response analyses. By integrating scientific software and industry standards, Discngine enables pharmaceutical and cosmetics firms to manage, visualize, and accelerate decision-making processes related to their research and development efforts.

PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

omicX operates a platform that facilitates access to bioinformatics tools for scientists and developers. Founded in 2012 and based in Le Petit Quevilly, France, the company offers OMICtools, a resource designed to help users navigate the vast array of biotechnology tools available. By leveraging collective intelligence in bioinformatics, omicX aims to exploit biological Big Data across various applications, including biotechnology, life sciences, medicine, agriculture, and industry. The platform not only provides information on tools for managing and analyzing extensive biological data but also fosters interaction within the scientific community by allowing users to pose questions, share expertise, and provide feedback on tools. This approach has established omicX as a trusted leader and reference point in bioinformatics, attracting users from prominent universities, medical institutions, pharmaceutical companies, and the biotech industry.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Ynsect is a biotechnology company based in Evry, France, that specializes in the production and processing of insects for sustainable animal feed and non-food applications. Founded in 2011, Ynsect operates insect vertical farms that convert insects into high-quality nutrition products, including proteins and lipids for livestock and pet diets. The company employs innovative bioconversion techniques to utilize organic resources, producing not only animal feed but also organic fertilizers, bioenergy, and other valuable materials. Ynsect's expertise in large-scale insect farming and automation has positioned it as a leading provider in the agro-food and environmental biotech sectors, making it a favored partner for agricultural professionals, research institutions, and investors.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.

Neovacs is a biotechnology company founded in 1993 as a spin-off from the Pierre & Marie Curie University in Paris by Professor Daniel Zagury, a prominent immunologist. The company specializes in the development of therapeutic vaccines known as "Kinoids," which are designed to treat a range of conditions including autoimmune diseases, allergies, and cancer. Neovacs holds an extensive patent portfolio and is recognized for its innovative approach to vaccine development, particularly in creating vaccines that target human cytokines and immunosuppressive viral proteins. Unlike traditional monoclonal antibody treatments that provide exogenous therapies, Neovacs' therapeutic vaccines promote a robust natural polyclonal antibody response in patients, positioning the company as a pioneer in the field of immunotherapy.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Theravectys is a biotechnology company focused on developing a novel vaccine platform aimed at treating and preventing a wide array of infectious diseases, cancers, and other medical conditions. The company’s innovative vaccination technology utilizes gene transfer into dendritic cells to modulate the immune response, enhancing the effectiveness of both prophylactic and therapeutic immunotherapies. Their lead product, a therapeutic vaccine targeting HIV/AIDS, has demonstrated promising efficacy and safety in non-human primate studies and is set to enter clinical trials. Through its diverse pipeline, Theravectys aims to provide healthcare providers with advanced treatment options that elicit a potent and targeted immune response in patients.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.